GSK plc (NYSE:GSK) is advancing its experimental seasonal influenza vaccine into late-stage development after encouraging mid ...

GSK plc GSK announced that it plans to advance the mRNA-based seasonal influenza (flu) vaccine candidate into late-stage development. This advancement is supported by positive results from a phase II ...

GSK plc (NYSE:GSK) plans to close its vaccine manufacturing facility in Dresden, Germany, by summer 2027, putting 641 jobs at ...

GSK plc GSK plans to launch a Phase 3 clinical trial in September for its experimental mRNA seasonal influenza vaccine after achieving superior immune responses in mid-stage testing compared to ...

GSK's pivot to high-margin vaccines and specialty drugs positions it for growth amid pharma shifts, but execution in competitive markets will be key. For investors in the United States and ...

GSK’s growth is increasingly specialty-led (HIV, RI&I, oncology), not just vaccines. ViiV’s long-acting injectables also tap into durable demand. Recent launches/approvals like Blenrep in r/r myeloma ...

GSK supports seasonal flu immunization in the US by shipping FLULAVAL (Influenza Vaccine) and FLUARIX (Influenza Vaccine) in advance of flu season PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK ...

GSK plc GSK is one of the key vaccine makers in the world, marketing vaccines to help prevent infectious diseases like Respiratory Syncytial Virus or RSV, meningitis, shingles, hepatitis and many more ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

GSK's leadership in vaccines and specialty medicines positions it for steady growth amid pharma shifts. For U.S. investors, its U.S. market exposure and dividend appeal matter now more than ever. ISIN ...